- Home
- OTLK vs CELU Comparison
OTLK vs CELU Comparison
Compare OTLK & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- CELU
- Stock Information
- Founded
- OTLK 2010
- CELU 2016
- Country
- OTLK United States
- CELU United States
- Employees
- OTLK N/A
- CELU N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- CELU Health Care
- Exchange
- OTLK Nasdaq
- CELU Nasdaq
- Market Cap
- OTLK 38.7M
- CELU 42.2M
- IPO Year
- OTLK 2016
- CELU N/A
- Fundamental
- Price
- OTLK $1.20
- CELU $1.38
- Analyst Decision
- OTLK Strong Buy
- CELU
- Analyst Count
- OTLK 5
- CELU 0
- Target Price
- OTLK $10.20
- CELU N/A
- AVG Volume (30 Days)
- OTLK 374.0K
- CELU 100.0K
- Earning Date
- OTLK 05-14-2025
- CELU 12-06-2024
- Dividend Yield
- OTLK N/A
- CELU N/A
- EPS Growth
- OTLK N/A
- CELU N/A
- EPS
- OTLK N/A
- CELU N/A
- Revenue
- OTLK N/A
- CELU $48,200,000.00
- Revenue This Year
- OTLK N/A
- CELU N/A
- Revenue Next Year
- OTLK $288.46
- CELU $233.89
- P/E Ratio
- OTLK N/A
- CELU N/A
- Revenue Growth
- OTLK N/A
- CELU 225.94
- 52 Week Low
- OTLK $0.87
- CELU $1.00
- 52 Week High
- OTLK $9.98
- CELU $5.69
- Technical
- Relative Strength Index (RSI)
- OTLK 34.06
- CELU 38.68
- Support Level
- OTLK $1.15
- CELU $1.64
- Resistance Level
- OTLK $1.31
- CELU $2.40
- Average True Range (ATR)
- OTLK 0.12
- CELU 0.21
- MACD
- OTLK -0.01
- CELU -0.02
- Stochastic Oscillator
- OTLK 20.45
- CELU 1.92
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.